Ok this may be premature, and I'll be sure to refresh all this...

Ok this may be premature, and I'll be sure to refresh all this after any forecasts are provided by management... but based on some conservative assumptions.. here I go

20 P/E is not uncommon for pharma companies, for a pharma with high growth potential like SPL - some could argue a much higher multiple... but lets use 20 for now.

370m shares on issue... so lets say in the mid-term after Vivagel is in the market ... they are able to generate $50m in annual earnings/profits.

That is $50m/370 = 13.5cents per share

At a P/E of 20, that is a share price of 20 x 13.5c = $2.70

Here is what the share price would be at other earnings milestones (annual)
$50m = 20x13.5c = $2.70c
$100m = 20x27c = $5.40c
$200m = 20x54c = $10.80c
$500m = 20x$1.35 = $27.03c

All of this is quite achievable if there is no significant dilution, Vivagel is successfully launched globally ... if DEP starts getting royalties.. the outlook could be even more bright!

What are we today? 88.5c ...

Make up your minds people ... how achievable is the above, given Vivagel + DEP programs that are already partnered with AstraZeneca generating milestones + royalties + any future DEP programs with AstraZeneca / shadow partners + our own DEP programs...